share_log

Blueprint Medicines | 8-K: Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT® / AYVAKYT ® (avapritinib) Full Year Revenue Guidance

SEC ·  Oct 30 04:11
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more